Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250014 Shandong Province, China.
Foshan Traditional Chinese Medicine Hospital, Foshan, 528000 Guangdong Province, China.
Biomed Res Int. 2020 Dec 9;2020:6692802. doi: 10.1155/2020/6692802. eCollection 2020.
Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI.
In Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, hospitalized or treated acute SCI patients were included in the study as the SCI group (SCI). At the same time, a normal control group (NC) matching the age and sex of the SCI group was recruited in the outpatient clinic. Once the two groups were enrolled, their demographics and clinical characteristics were collected immediately. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum CCL21 levels within 24 hours of admission. Three months later, the Montreal Cognitive Assessment (MoCA) was used to test the cognitive function of the population.
A total of 84 SCI patients and 49 NC populations were eligible for inclusion in the study. There was no significant statistical difference in the demographics and clinical characteristics (age, gender, BMI, TG, LDL-C, FBG, SBP, and DBP) between the two groups ( > 0.05). Compared with the NC group, the SCI group had a higher serum CCL21 level ( < 0.001) and a lower MoCA score ( < 0.001). Serum CCL21 level in SCI was negatively correlated with MoCA score ( = 0.023). Multivariable analyses showed that serum CCL21 level is an independent prognostic factor of cognitive impairment in SCI.
MoCA score has a linear relationship with serum CCL21 quartile, and SCI cognitive function has a negative correlation with serum CCL21. Serum CCL21 is an independent risk factor for cognitive impairment after SCI.
认知障碍被认为是脊髓损伤（SCI）的重要并发症，但其潜在机制尚不清楚。本研究旨在探讨血清 CCL21 是否可作为 SCI 认知障碍的潜在生物标志物。
在山东第一医科大学第一附属医院颈肩腰腿痛医院，纳入住院或接受急性 SCI 治疗的患者作为 SCI 组（SCI）。同时，在门诊招募与 SCI 组年龄和性别相匹配的正常对照组（NC）。两组入组后，立即收集其人口统计学和临床特征。入院后 24 小时内，采用酶联免疫吸附试验（ELISA）检测血清 CCL21 水平。3 个月后，采用蒙特利尔认知评估（MoCA）测试人群的认知功能。
共有 84 例 SCI 患者和 49 例 NC 人群符合纳入标准。两组在人口统计学和临床特征（年龄、性别、BMI、TG、LDL-C、FBG、SBP 和 DBP）方面无统计学差异（>0.05）。与 NC 组相比，SCI 组血清 CCL21 水平较高（<0.001），MoCA 评分较低（<0.001）。SCI 组血清 CCL21 水平与 MoCA 评分呈负相关（=0.023）。多变量分析表明，血清 CCL21 水平是 SCI 认知障碍的独立预后因素。
MoCA 评分与血清 CCL21 四分位呈线性关系，SCI 认知功能与血清 CCL21 呈负相关。血清 CCL21 是 SCI 后认知障碍的独立危险因素。
